IBD Alliance

The IBD Alliance at the Karolinska Institutet/Hospital is a network of physicians and researchers (physicians/non-physicians) interested in IBD. The aim is to promote the interaction between clinical care and research in IBD.

Inflammatory bowel disease (IBD) affects more than 60 000 individuals alone in Sweden. It is generally divided into ulcerative colitis (UC), Crohn’s disease (CD), and unspecified IBD (IBD-U). IBD has undergone major changes over time. While the mortality in the 1950s was 30-40%, new treatment has meant that death is now rare in IBD. Initial treatment was restricted to bowel surgery (especially colectomy), until steroids were introduced and later 5-ASA and thiopurines. Today, IBD is one of the most exciting areas for new treatments. TNF-blockers and other biologics have shown great effect. Also the interplay between microbiota and dietary intake yields promises (the NOD2 mutation plays an important role in Crohn’s disease and recognises bacterial peptides). In children enteral nutrition often has a substantial effect on disease activity, and fecal transplantation is a potential treatment.
The increased survival in IBD means that physicians more and more will have to focus on long-term complications such as colorectal cancer, lymphoma and opportunistic infections. Patients are followed by regular visits to physicians, dieticians, dedicated IBD nurses etc, and IBD-specific diagnostics include fecal calprotectin and endoscopy and increasingly ultrasound and magnetic resonance.
Professor Jonas Ludvigsson is the coordinator of the IBD Alliance network.


Almer, Sven  
Arnell, Henrik  
Askling, Johan  
Backman, Ann-Sofie  
Bergquist, Annika  
Björk, Jan  
Bresso, Francesca  
Browaldh, Lars  
Casswall, Thomas  
D'Amato, Mauro  
Davidsdóttir, Loa  
Eberhardson, Michael  
Ekbom, Anders  
Finkel, Yigael  
Hedin, Charlotte  
Hultcrantz, Rolf  
Ideström, Maja  
Jonsson-Rolandsdottir, Helena  
Kapraali, Marjo  
Karlsson, Annika  
Kharrazi, Gandom  
Krantz, Åsa  
Lepp, Johanna  
Lindfors, Ulrik  
Lindgren, Fredrik  
Lindström, Lina  
Lördal, Mikael  
Malmborg, Petter  
Mellander, Marie-Rose  
Mjösberg, Jenny  
Mouratidou, Natalia  
Nilsson, Per  
Olen, Ola  
Svensson, Mattias  
Tapsas, Dimitros  
Thulin, Helena  
Törkvist, Leif  
Uusijärvi, Agneta  
Zetterström, Cecilia  

Ongoing projects

Name Location Project title   Project summary
Ludvigsson, Jonas: network coordinator KI Risk of cancer in IBD - a registry-based study   The primary objective is to evaluate the risk of cancer in children and adults with IBD taking disease location, grade of inflammation and treatment into account.
Bresso, Francesca KI Role of epigenetic modifications in IBD   To evaluate epigenetic modifications in IBD, causative and regulatory role, related gene-environment interaction and identification of putative biomarkers
-"'- -"- Gastromics: Biobank at Gastrocentrum KS   Build a biobank at gastrocentrum, with collection of data and material, diagnose independent, prospective, possibly linked to registries. Gastromics: multi-omics project based on it.
Eberhardson, Michael KS Selective targeting of pro-inflammatory immune cells for the treatment of inflammatory bowel disease   Selective chemokine-based apheresis may represent a safe and valuable addition to current anti-inflammatory therapies. The aim of this research programme is to perform studies of chemokine-loaded leukapheresis column (TLA Gut) in inflammatory bowel disease.
Ekbom, Anders KI Chronic inflammation - will it be less harmful after anti-inflammatory therapy?   Follow-up of different patient groups with chronic inflammation with regards to morbidity, mortality utilization of health care, following different interventions, including surgery.
Davidsdóttir, Loa KS Women and men of fertile age with IBD: fertility, fecundity, pregnancy and delivery in pairs with at least one person has IBD, and follow-up of children born to IBD patients    
Finkel, Yigael Södersjukhuset Infliximab - trough levels and disease activity scoring in ped CD    
-"'- -"'- Immunological and clinical evaluation of enteral nutrition in remission treatment of newly diagnosed CD    
-"'- -"'- Immunological and clinical evaluation of granulocyte-monocyte apheresis for remission treatment in newly diagnosed UC    
Hedin, Charlotte KS Altered intestinal microbiota and blood T-cell phenotype are shared by Crohn’s disease patients and their unaffected siblings   This project aimed to delineate the genetic, immune and microbiological profile of CD patients, their siblings and controls and also to determine which factors discriminate groups.
Jonsson-Rolandsdottir, Helena Södersjukhuset Serum levels of Infliximab and the effect of treatment in children and youth with IBD    
-"'- -"'- Immunologic profile in children and youth who are diagnosed with ulcerus colitis and who are treated with Aferes    
-"'- -"'- Immunologic profile in children and youth who are diagnosed with Crohn's disease and are given med Enteral Nutrition treatment    
Kharrazi, Gandom KS Outcome of combination therapy in pediatric inflammatory bowel disease   To chart the therapeutic outcome of pediatric IBD
Lindgren, Fredrik KS Pancreatic affliction in childhood IBD with or without AILD (Autoimmune Liver Disease)   To investigate grade of pancreatic affliction (elevated or decreased pancreatic enzymes, pancreatic exocrine insufficiency and pancreatitis) in other GI-disorders such as IBD and AILD such as AIH and PSC. 
-"'- -"'- Efficacy and Safety of Adacolumn® Granulocyte, Monocyte/Macrophage Adsorptive (GMA) Apheresis in Children and Adolescents with Moderate Active Ulcerative Colitis (the ADAPT study)   To report efficacy and safety results for Adacolumn® Granulocyte, Monocyte/Macrophage Adsorptive (GMA) Apheresis seen in adult UC patients since over a decade are comparable to a pediatric UC population, and whether there were any additional specific risks in pediatric UC patients when treated with Adacolumn.
Lindström, Lina KS  Recurrence of PSC after liver transplantation   The aim of the study is to identify/confirm risk factors for recurrent PSC in a large and well characterized cohort of PSC patients. Emphasis on IBD-related risk factors such as inflammatory activity and colectomy.
Malmborg, Petter KS Prognosis of pediatric IBD   Some studies suggest that childhood-onset of disease represents a more aggressive phenotype of IBD. We are studying the presentation and progression of patients diagnosed with IBD during childhood in a population-based cohort from northern Stockholm County 1990-2007. 
Nilsson, Per KS  Studies on colectomized IBD patients   Mortality, reconstruction rate and patency of reconstruction in a 10-year cohort of operated IBD-patients
-"'- -"'- Surgical outcomes in Swibreg   Early project - exploratory studies
Olén, Ola KI Etiology of Inflammatory bowel disease    
-"'- -"'- Prognosis of Inflammatory bowel disease    
Svensson, Mattias KS Exploration of stromal cell and neutrophil interactions contributing to the pathogenesis of inflammatory bowel disease   We aim to increase the knowledge of how tissue inflammation persists and how treatment and management of IBD patients can be improved. We will on the one hand investigate how stromal cells affect neutrophils, and on the other hand how neutrophils affect stromal cells to perpetuate inflammation and contribute to IBD pathogenesis.
Uusijärvi, Agneta KI A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Pediatric Patients with Moderately to Severely Active Crohn’s Disease   The main aim is to evaluate long-term safety of Humira® in pediatric patients with moderately to severely active CD who are prescribed and treated in accordance with the approved local Humira® product label under the conditions of routine clinical setting. Patients being prescribed and treated with conventional immunosuppressant therapy with no concurrent biologic use will also be enrolled as a reference group. 

Selected publications


Gastrointestinal diseases